iNtRON Biotechnology Inc
KOSDAQ:048530
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
iNtRON Biotechnology Inc
Total Receivables
iNtRON Biotechnology Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
i
|
iNtRON Biotechnology Inc
KOSDAQ:048530
|
Total Receivables
₩1.1B
|
CAGR 3-Years
-75%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-13%
|
|
|
Celltrion Inc
KRX:068270
|
Total Receivables
₩2T
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Total Receivables
₩248.7m
|
CAGR 3-Years
296%
|
CAGR 5-Years
78%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Receivables
₩38.4B
|
CAGR 3-Years
61%
|
CAGR 5-Years
70%
|
CAGR 10-Years
57%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Total Receivables
₩59.6B
|
CAGR 3-Years
370%
|
CAGR 5-Years
112%
|
CAGR 10-Years
N/A
|
|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
Total Receivables
₩5.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
iNtRON Biotechnology Inc
Glance View
iNtRON Biotechnology, Inc. is a Korea-based company principally engaged in the biotechnology industry. The Company operates its business through two main divisions: genetic reagent division and molecular diagnostics division. Its genetic reagent division is involved in the research and development of reagents, which are under the brand names of Maxime and pLUG for life science research. Its molecular diagnostics division is engaged in the development and production of nucleic acid tester for infectious diseases. It also engages in the operation of veterinary antibiotic alternative business and new biopharmaceuticals development business. The Company distributes its products within domestic market and to overseas markets.
See Also
What is iNtRON Biotechnology Inc's Total Receivables?
Total Receivables
1.1B
KRW
Based on the financial report for Dec 31, 2025, iNtRON Biotechnology Inc's Total Receivables amounts to 1.1B KRW.
What is iNtRON Biotechnology Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
-13%
Over the last year, the Total Receivables growth was -11%. The average annual Total Receivables growth rates for iNtRON Biotechnology Inc have been -75% over the past three years , -38% over the past five years , and -13% over the past ten years .
